| Institution: | 1. Pharmacokinetics, Dynamics and Metabolism-New Biological Entities, Pfizer, Andover, MA, United States;2. Pharmacokinetics, Dynamics and Metabolism-New Biological Entities, Pfizer, Cambridge, MA, United States;3. Pharmacokinetics, Dynamics and Metabolism-New Biological Entities, Pfizer, San Diego, CA, United States;1. Bristol-Myers Squibb, Clinical Pharmacology and Pharmacometrics, Route 206 & Province Line Road, Princeton, New Jersey 08543;2. Leiden University, Faculty of Science, Leiden Academic Centre for Drug Research, Drug Delivery Technology, Einsteinweg 55, 2333 CC Leiden, Netherlands;3. Amgen, Thousand Oaks, California 91320;4. F.Hoffman-La Roche Ltd, Pharmaceuticals Division, CH-4070 Basel, Switzerland;5. Pfizer, PDM Immunogenicity Sciences, Andover, Massachusetts 01810;6. Halozyme Therapeutics 11388 Sorrento Valley Road, San Diego, California 92121;7. Merck Sharp & Dohme Corp., 2000 Galloping Hill Road, K-15 E-410C, Kenilworth, New Jersey 07033;1. Departamento de Física, CUCEI, Universidad de Guadalajara, Av. Revolución 1500, Guadalajara, CP 44420, Jalisco, Mexico;2. Institut de Science des Matriaux de Mulhouse, UMR 7361 CNRS-UHA, 15 rue Jean Starcky, 68057 Mulhouse, France;3. Theoretical Division, T-4, Los Alamos National Laboratory, and the New Mexico Consortium, Los Alamos, NM 87544, USA |
